Interleukin-6-knockdown of chimeric antigen receptor-modified T cells significantly reduces IL-6 release from monocytes

BACKGROUND: T cells expressing a chimeric antigen receptor (CAR) engineered to target CD19 can treat leukemia effectively but also increase the risk of complications such as cytokine release syndrome (CRS) and CAR T cell related encephalopathy (CRES) driven by interleukin-6 (IL-6). Here, we investig...

Descripción completa

Detalles Bibliográficos
Autores principales: Kang, Liqing, Tang, Xiaowen, Zhang, Jian, Li, Minghao, Xu, Nan, Qi, Wei, Tan, Jingwen, Lou, Xiaoyan, Yu, Zhou, Sun, Juanjuan, Wang, Zhenkun, Dai, Haiping, Chen, Jia, Lin, Guoqing, Wu, Depei, Yu, Lei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7278071/
https://www.ncbi.nlm.nih.gov/pubmed/32523801
http://dx.doi.org/10.1186/s40164-020-00166-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7278071/
https://www.ncbi.nlm.nih.gov/pubmed/32523801
http://dx.doi.org/10.1186/s40164-020-00166-2

Ejemplares similares